Capricor Therapeutics (CAPR) shares rallied 18.2% in the last trading session to close at $5.97. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 10.8% gain over the past four weeks. The sharp upsurge in Capricor's shares can be attributed to the company's anticipated regulatory update on deramiocel for Duchenne muscular dystrophy (DMD) in an investor webcast scheduled for Sept. 24. The webcast will include th ...